We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2023-05-31 Interview with Redeye

Redeye interviews CEO Göran Forsberg about the new readout from trials in non-small cell lung cancer presented at ASCO 2023

Watch the interview here

2023-05-26 Interview with DiTV

DiTV interviews CEO Göran Forsberg about the promising interim efficacy results for nadunolimab in lung cancer to be presented at ASCO 2023

Watch the interview here

2023-05-23 CEO speech AGM 2023

Watch the CEO speech here

”2023 is off to a very strong start with promising progress in our projects. I am convinced that Cantargia will maintain this positive development during the rest of the year, as we can look forward to additional results and start of new activities.”


Göran Forsberg
CEO Cantargia